Last updated on July 2017

Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis X) in Patients With Dry Eye Disease


Brief description of study

This study will evaluate a new ophthalmic formulation of cyclosporine (Restasis® X) in patients with moderate to severe dry eye disease in two stages. Up to 3 doses will be studied in Stage 2 based on results from Stage 1. No patients participating in Stage 1 will participate in Stage 2 of this study.

Clinical Study Identifier: NCT02013791

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Clinical Trials Registry Team

Sall Research Medical Center
Artesia, CA United States
  Connect »

Clinical Trials Registry Team

Lugene Eye Institute
Glendale, CA United States
  Connect »

Clinical Trials Registry Team

Lakeside Vision Center
Irvine, CA United States
  Connect »

Clinical Trials Registry Team

Dr. Nanduri's Associated Eye Surgeons Medical Group/Envision Eye
La Jolla, CA United States
  Connect »

Clinical Trials Registry Team

Scripps Clinic
La Jolla, CA United States
  Connect »

Clinical Trials Registry Team

M.D. Med Associates
Newport Beach, CA United States
  Connect »

Clinical Trials Registry Team

Wolstan & Goldberg Eye Associates
Torrance, CA United States
  Connect »

Clinical Trials Registry Team

Vision Institute
Colorado Springs, CO United States
  Connect »

Clinical Trials Registry Team

Johns Hopkins University - Wilmer Eye Institute
Baltimore, MD United States
  Connect »

Clinical Trials Registry Team

Abrams Eye Institute
Las Vegas, NV United States
  Connect »

Clinical Trials Registry Team

Eye Centers of Racine and Kenosha
Kenosha, WI United States
  Connect »